Our Vision
Our vision is a future where aging-related diseases are no longer inevitable but manageable through therapies that enhance healthspan across the population.
Our Mission
At ElixIRA Pharma AG, our mission is to develop innovative therapies that extend healthy lifespan by targeting the fundamental biology of aging. We are committed to restoring cellular resilience and improving quality of lifeânot just treating disease symptoms.
Proof-of-Concept Model: DM1
Myotonic Dystrophy Type 1 (DM1) mirrors many hallmarks of agingâmitochondrial dysfunction, stem cell exhaustion, proteostasis lossâoffering a unique accelerated-aging platform for testing next-gen longevity therapeutics.
Explore DM1 ModelOur Lead Asset: ELX019
A disease-modifying AMPK/mTORC1 combination therapy currently in preclinical development, with rapid path to Phase I/II.
View PipelineLeadership Team
Chief Executive Officer & Co-Founder
Over 25 years of global pharmaceutical leadership experience, with an MBA in Marketing and executive education from Chicago Booth & INSEAD.
Chief Scientific Officer
PhD in Life Sciences with 20+ years in academic and industry research, specializing in neuroimmunology and drug discovery.
Chief Operations Officer & Co-Founder
Over a decade of project management and operational expertise, with a Masterâs in Marketing and executive training in Economics in Switzerland.
Get in Touch
We welcome your inquiries, feedback, and collaboration opportunities to advance our mission in DM1 and extend healthy lifespan.
Contact Us